- $2.85m
- $1.31m
- $2.00m
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
BioAtla Q4 net loss narrows on lower expenses
Brief: BioAtla Q4 Net Income USD -9.784 Million
Brief: Bioatla Inc - Announces 70% Workforce Reduction - SEC Filing
Brief: Bioatla Announces Formal Process To Evaluate Strategic Options To Monetize Assets
BioAtla Q3 net loss widens to $15.8 mln
Brief: BioAtla Q3 Net Income USD -15.778 Million
Brief: BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
Brief: BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 Results
Bioatla Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: BioAtla Q2 Net Income USD -18.711 Million
Bioatla Inc expected to post a loss of 34 cents a share - Earnings Preview
Bioatla Inc reports results for the quarter ended March 31 - Earnings Summary
Bioatla Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: BioAtla Announces Poster Presentations At The 2025 American Association For Cancer Research (Aacr) Annual Meeting
Bioatla Inc reports results for the quarter ended December 31 - Earnings Summary